Our ambition with this newsletter is to provide you with insight into our strategy and portfolio and share market insights from our network of industry analysts and thought leaders. We are very interested in your feedback of how we can improve our communications with you and which newsletter topics you are most interested in.
Bernard et al..... send your learned comments to management as they are so very interested
Elbit Medical Technologies Ltd. (TASE:EMTC) today announced that its subsidiary InSightec Image Guided Treatment Ltd., in which it holds a 31.6% stake, had signed a non-binding memorandum of understanding with a major international imaging company for joint adaptation of their devices.
Siemens is one of the world's leading manufacturers of imaging devices, together with GD and Royal Philips. Last year, GE, formerly the most prominent investor in InSightec and also its marketer, sold part of its holdings in the company, mainly to the York Capital Management fund, the new controlling shareholder in Insightec.
Essential tremor is a chronic and often progressive condition that usually affects the arms and hands on both sides of the body and an estimated 10 million people in the U.S. suffer from it, according to the International Essential Tremor Foundation (IETF).
The University of Maryland Medical Center is one of eight sites that is participating in an international clinical trial to treat the condition with MRgFUS. The initial results of the trial were promising – all of the patients showed immediate improvement in their tremor.
One of the physicians involved in that study predicts that the FDA will approve MRgFUS as a standard secondary essential tremor therapy on one side of the brain soon. If the results are still promising in the long-term, maybe it will be approved for both sides of the brain.
Therapeutics Inc (NASDAQ:PSTI) Improves in 2015 Q3
17 investment managers increased or started new positions, while 11 decreased and sold stock positions in Pluristem Therapeutics Inc.
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) has a total of 3 Strong Buy advice and 0 Strong Sell calls as of 2016-04-13.
One month earlier, the total count of strong buy recommendations was 3 and strong sell was 0. The mean analyst rating was 1.
reminds me of an old joke:
Mike brags: one more inch down there, i would be a king!
Says his friend: one less you would be a queen.
Got it allo_g?
:-) :-) :-)
There is no doubt that obtaining patents the company is a good thing, but it is possible that it is precisely the words of Chairman and CEO PLURISTEM, Zami Aberman, are the ones who bring optimism among traders: "We are actively negotiating with several pharmaceutical companies that have the potential to become our partners" , the company said in a statement. Also, Aberman said that "recent patent approvals received in Japan are strengthening our intellectual property position in the Japanese market in general and in particular."